At Biocodex, we believe that understanding – and acting on – microbiota is important to the future of human health. Rooted in our heritage as pioneer in gut microbiota, we aim to become the global #1 in microbiota care.
Since the launch of the world’s first probiotic drug, Saccharomyces boulardii CNCM I-745® in 1953, Biocodex has evolved from a pioneering French start-up to an global key player in the microbiota realm.
At Biocodex we are devoted to nurturing expertise in human microbiota and elevating their impact on our health. As a pioneer in therapeutic probiotics, we aim to become the leader in microbiota care.
Our focus on microbiota care is threefold:
Biocodex provides SOLUTIONS to improve microbiota health with our unique Saccharomyces boulardii CNCM I-745® probiotic drug, our innovative new Symbiosys® product range, and early-stage investment in start-up companies.
The Biocodex Microbiota Foundation advances SCIENTIFIC BREAKTHROUGHS by funding academic research in microbiota.
The Biocodex Microbiota Institute EDUCATES the general public and healthcare professionals on the growing importance of microbiota on healthcare and well-being.
Chief Executive Officer at BIOCODEX
Biocodex’s solutions for microbiota care
We provide solutions protect, restore and reinforce the action of gut microbiome to treat and prevent human diseases or conditions. These solutions include:
- Our unique probiotic drug Saccharomyces boulardii CNCM I-745®
- Our innovative product range Symbiosys®
- Early-stage investment in start-up companies
The Biocodex Microbiota Institute
The Biocodex Microbiota Institute is an international knowledge hub dedicated to microbiota by:
- Providing healthcare professionals with the latest scientific news and data including the Institute’s exclusive content such as Microbiota magazine, thematic folders, and interviews with experts…
- Enlightening the general public on the importance of microbiota in healthcare and well-being
The Biocodex Microbiota Foundation
The Biocodex Microbiota Foundation aims to enhance scientific knowledge on human microbiota and their interaction with various pathologies to help improve human health and well-being:
- Contribute to the development of scientific knowledge in the field of microbiota.
- Encourage research.
- Favor to improving people’s health and well-being worldwide.
Want to know more?
Biocodex is a family-owned company founded 70 years ago to market the world's first probiotic yeast strain, Saccharomyces boulardii CNCM I-745®. Biocodex has since expanded its expertise in gut microbiota, evolving from French pioneer to an international player in the microbiota realm.
Biocodex develops and markets drugs for patients with severe orphan diseases. In the early 1990’s, we developed an anti-epileptic drug indicated for a newly discovered rare and severe epileptic disorder. Since then, we have been committed to raising awareness of rare epilepsies alongside healthcare professionals, patients and caregivers.
As a pioneer in feminine hygiene products and a market leader in France and Belgium, we aim to continue supporting women throughout the world daily and at every stage of their lives. We innovate constantly to bring effective solutions for women's health, comfort and well-being. Our commitment to women includes effective quality products, expert advice and a responsible attitude to the environment and society at large.